Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant mFOLFOXIRI Plus Bevacizumab Versus Induction FOLFOX Followed by Concomitant Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: Multicenter Randomized Phase III Trial

NCT04215731 is registered in ClinicalTrials.gov with Yanhong Deng as lead sponsor.

NCT NCT04215731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04215731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant mFOLFOXIRI Plus Bevacizumab Versus Induction FOLFOX Followed by Concomitant Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: Multicenter Randomized Phase III Trial
Lead sponsor
Yanhong Deng
Phase
Phase 3
Overall status
Recruiting
Start date
March 27, 2020
Completion date
June 1, 2029
Enrollment
582 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer